^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE3 inhibitor

    Related drugs:
    4d
    AVATAR-HF: Artificial Voice Analysis and Telemonitoring for Heart Failure. A Feasibility Study (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, Niguarda Hospital
    New trial
    6d
    A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD (clinicaltrials.gov)
    P3, N=387, Not yet recruiting, Haisco Pharmaceutical Group Co., Ltd.
    New P3 trial
    10d
    A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder (clinicaltrials.gov)
    P2, N=195, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    18d
    A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD (clinicaltrials.gov)
    P3, N=376, Recruiting, Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    18d
    A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Guangdong Hengrui Pharmaceutical Co., Ltd
    New P2 trial
    19d
    Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov)
    P2, N=50, Recruiting, Haisco Pharmaceutical Group Co., Ltd. | Active, not recruiting --> Recruiting
    Enrollment open
    20d
    Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Haisco Pharmaceutical Group Co., Ltd.
    New P3 trial
    25d
    TAM-AMIN-UAS: Tamsulosin and Intraureteral Aminophylline for Ureteral Access During RIRS (clinicaltrials.gov)
    P2, N=322, Recruiting, Beni-Suef University
    New P2 trial
    27d
    Intravesical Aminophylline for Urgent Ureteral Stenting in Acute Calculous Anuria (clinicaltrials.gov)
    P2, N=72, Recruiting, Beni-Suef University
    New P2 trial
    27d
    Intravesical Aminophylline to Facilitate Ureteroscopic Access in Children With Distal Ureteral Stones. (clinicaltrials.gov)
    P2, N=60, Recruiting, Beni-Suef University
    New P2 trial
    1m
    Cilostazol inhibits TGF-α-induced migration of hepatocellular carcinoma cells by activating PPARγ. (PubMed, Biochem Biophys Res Commun)
    We also found that PPARγ activators, ciglitazone and pioglitazone, significantly inhibited the TGF-α-induced migration of HuH7 cells. Cilostazol and dipyridamole also inhibited the activation of AKT but not EGFR. Taken together, these results strongly suggest that cilostazol and dipyridamole inhibit TGF-α-induced HCC cell migration by suppressing the AKT pathway through PPARγ activation.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    1m
    Neuroinflammatory and Synaptic Roles of Glial Cells in Autism Spectrum Disorder. (PubMed, CNS Neurol Disord Drug Targets)
    Interventions to correct glial dysfunction-e.g., anti-inflammatory medication (e.g., minocycline, ibudilast), gene therapy, and stem cell therapy-are investigated for their potential to restore glia to normal and diminish ASD symptoms. Understanding glial-neuronal communication mechanisms and their role in neuroinflammation offers a hopeful future for accurate, target-specific treatment. Advances in the elucidation of these processes will foretell an enormous increase in therapeutic efficacy and quality of life for individuals with ASD.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6)
    |
    Eyevinal (ibudilast) • minocycline